The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Psychotic Depression

REFERENCES

• Adamson M. White paper: blueprint for collaboration. Symposium on diffusion, adoption, and maintenance of psychiatric treatment algorithms. International Psychopharmacology Algorithm Project, Buffalo, NY 2006
   Google Scholar
• Adli M, Bauer M, Rush A J. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 2006; 59: 1029–38
   PubMed Web of Science ®Google Scholar
• Gilbert D A, Altshuler K Z, Rago W V, et al. Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998; 59: 345–51
   PubMed Web of Science ®Google Scholar
• Osser D. Guidelines and algorithms for psychopharmacology: what is their role in 2007?. Psychiatr Times 2007; 21: 55–9; 79
   Google Scholar
• Trivedi M H, Fava M, Marangell L B, Osser D N, Shelton R C. Use of treatment algorithms for depression. J Clin Psychiatry 2006; 67: 1458–65
   Google Scholar
• Osser D N. A systematic approach to the classification and pharmacotherapy of nonpsychotic major depression and dysthymia. J Clin Psychopharmacol 1993; 13: 133–44
   PubMed Web of Science ®Google Scholar
• Osser D N, Patterson R D. Algorithms for the pharmacotherapy of depression: part one. Dir Psychiatry 1998; 18: 303–18
   Google Scholar
• Osser D N, Patterson R D. Algorithms for the pharmacotherapy of depression: part two. Dir Psychiatry 1998; 18: 319–36
   Google Scholar
• Dantzler A, Osser D N. Algorithms for the pharmacotherapy of acute depression in patients with bipolar disorder. Psychiatr Ann 1999; 29: 270–84
   Web of Science ®Google Scholar
• Johnson J, Jowarth E, Weissman M M. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991; 48: 1075–81
   PubMed Web of Science ®Google Scholar
• Ohayon M, Schatzberg A. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002; 159: 1855–61
   PubMed Web of Science ®Google Scholar
• Coryell W, Lavori P, Endicott J, Keller M, VanEerdewegh M. Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six-to 24-month follow-up. Arch Gen Psychiatry 1984; 41: 787–91
   PubMed Web of Science ®Google Scholar
• Meyers B S, Greenberg R. Late-life delusional depression. J Affect Disord 1986; 11: 133–7
   Google Scholar
• Spiker D G, Weiss J C, Dealy R S, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430–6
   PubMed Web of Science ®Google Scholar
• Nelson J, Price L, Jatlow P. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am J Psychiatry 1986; 143: 1151–4
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. APA, Washington, DC 1980
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. American Psychiatric Press, Washington, DC 1987
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. APA, Washington, DC 1994
   Google Scholar
• Rothschild A, Williamson D, Tohen M, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24: 365–73
   PubMed Web of Science ®Google Scholar
• Keller J, Schatzberg A F, Maj M. Current issues in the classification of psychotic major depression. Schizophr Bull 2007; 33: 877–85
   PubMed Web of Science ®Google Scholar
• Schatzberg A F, Rothschild A J. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. Am J Psychiatry 1992; 149: 733–45
   PubMed Web of Science ®Google Scholar
• Bond T C, Rothschild A J, Lerbinger J, Schatzberg A F. Delusional depression, family history, and DST response: a pilot study. Biol Psychiatry 1986; 21: 1239–46
   Google Scholar
• Nelson J, Davis J. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997; 154: 1497–503
   PubMed Web of Science ®Google Scholar
• Anton R. Urinary free cortisol in psychotic depression. Biol Psychiatry 1987; 22: 24–34
   PubMed Web of Science ®Google Scholar
• Arana G, Ross J, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatry 1985; 42: 1193–204
   PubMed Web of Science ®Google Scholar
• Brown R P, Stoll P M, Stokes P E, et al. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatric Res 1988; 23: 167–78
   PubMed Web of Science ®Google Scholar
• Thase M, Kupfer D, Ulrich R. Electroencephalographic sleep in psychotic depression: a valid subtype?. Arch Gen Psychiatry 1986; 43: 886–93
   PubMed Web of Science ®Google Scholar
• Contreras F, Menchon J M, Urretavizcaya M, Navarro M A, Vallejo J, Parker G. Hormonal differences between psychotic and non-psychotic melancholic depression. J Affect Disord 2007; 100: 65–73
   PubMed Web of Science ®Google Scholar
• Keller J, Flores B, Gomez R G, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006; 60: 275–81
   PubMed Web of Science ®Google Scholar
• Hill S, Keshavan M, Thase M, Sweeney J. Neuropsychological dysfunction in antipsychotic-naïve first-episode unipolar psychotic depression. Am J Psychiatry 2004; 161: 996–1003
   PubMed Web of Science ®Google Scholar
• Schatzberg A F, Posener J A, DeBattista C, Kalehzan B M, Rothschild A J, Shear P K. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 2000; 157: 1095–100
   PubMed Web of Science ®Google Scholar
• Rothschild A. Challenges in the treatment of depression with psychotic features. Biol Psychiatry 2003; 53: 680–90
   PubMed Web of Science ®Google Scholar
• Vythilingam M, Chen J, Bremner J D, Mazure C M, Maciejewski P K, Nelson J C. Psychotic depression and mortality. Am J Psychiatry 2003; 160: 574–6
   PubMed Web of Science ®Google Scholar
• Rothschild A J, Benes F, Hebben N, et al. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry 1989; 26: 565–75
   PubMed Web of Science ®Google Scholar
• Targum S D, Rosen L N, DeLisi L E, Weinberger D R, Citrin C M. Cerebral ventricular size in major depressive disorder: association with delusional symptoms. Biol Psychiatry 1983; 18: 329–36
   Google Scholar
• Chan C H, Janicak P G, Davis J M, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 1987; 48: 197–200
   PubMed Web of Science ®Google Scholar
• Charney D S, Nelson J C. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 1981; 138: 328–33
   PubMed Web of Science ®Google Scholar
• Nelson J C, Bowers M B, Jr. Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 1978; 35: 1321–8
   PubMed Web of Science ®Google Scholar
• Andreescu C, Mulsant B H, Peasley-Miklus C, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry 2007; 68: 194–200
   PubMed Web of Science ®Google Scholar
• Petrides G, Fink M, Husain M M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001; 17: 244–53
   PubMed Web of Science ®Google Scholar
• Perry P, Morgan D, Smith R, Tsuang M. Treatment of unipolar depression accompanied by delusions. J Affect Disord 1982; 4: 195–200
   Google Scholar
• Rothschild A J. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 237–52
   PubMed Web of Science ®Google Scholar
• Pande A, Grunhaus L, Hasket R, Greden J F. Electroconvulsive therapy in delusional and nondelusional depressive disorder. J Affect Disord 1990; 19: 215–9
   PubMed Web of Science ®Google Scholar
• Parker G, Hazdi-Pavlovic D, Hickie I, et al. Distinguishing psychotic and non-psychotic melancholia. J Affect Disord 1991; 22: 135–48
   PubMedGoogle Scholar
• Olfson M, Marcus S, Sackiem H A, Thompson J, Pincus H A. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 1998; 155: 22–9
   PubMed Web of Science ®Google Scholar
• Birkenhäger T K, Renes J W, Pluijms E M. One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. J Clin Psychiatry 2004; 65: 87–91
   Google Scholar
• Birkenhäger T K, Van den Broek W W, Mulder P G, De Lely A. One-year outcome of psychotic depression after successful electroconvulsive therapy. J ECT 2005; 21: 221–6
   PubMed Web of Science ®Google Scholar
• Tsuchiyama K, Nagayama H, Yamada K, Isogawa K, Katsuragi S, Kiyota A. Predicting efficacy of electroconvulsive therapy in major depressive disorder. Psychiatry Clin Neurosci 2005; 59: 546–50
   Google Scholar
• Sackeim H A, Haskett R F, Mulsant B H, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285: 1299–307
   PubMed Web of Science ®Google Scholar
• Meyers B S, Klimstra S A, Gabriele M, et al. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry 2001; 9: 415–22
   PubMed Web of Science ®Google Scholar
• Lisanby S H. Electroconvulsive therapy for depression. N Engl J Med 2007; 357: 1939–45
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. American Psychiatric Press, Washington, DC 2001
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of major depressive disorder (revision). Am J Psychiatry 2000; 157(4 suppl)1–45
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. NICE, London 2004
   Google Scholar
• Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen W A. Pharmacological treatment for psychotic depression. Cochrane database of systematic reviews 2005; 4: CD004044
   Google Scholar
• Wijkstra J, Lijmer J, Balk F J, Geddes J R, Nolen W A. Pharmacological treatment for unipolar psychotic depression. Br J Psychiatry 2006; 188: 410–5
   PubMed Web of Science ®Google Scholar
• Glassman A H, Roose S P. Delusional depression. Arch Gen Psychiatry 1981; 38: 424–7
   PubMed Web of Science ®Google Scholar
• Chan C H, Janicak P G, Davis J M, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 1987; 48: 197–200
   PubMed Web of Science ®Google Scholar
• Spiker D G, Perel J M, Hanin I, et al. The pharmacological treatment of delusional depression: part II. J Clin Psychopharmacol 1986; 6: 339–42
   PubMed Web of Science ®Google Scholar
• Anton R, Burch E. Amoxapine vs amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990; 147: 1203–8
   PubMed Web of Science ®Google Scholar
• Mulsant B H, Sweet R A, Rosen J, et al. A randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry 2001; 62: 597–604
   PubMed Web of Science ®Google Scholar
• Vattakatuchery J J. Drug treatment for psychotic depression. Br J Psychiatry 2006; 189: 383
   Google Scholar
• Rothschild A J, Samson J A, Bessette M P, Carter-Campbell J T. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54: 338–42
   PubMed Web of Science ®Google Scholar
• Wolfersdorf M, Barg T, König F, Leibfarth M, Grünewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 1995; 28: 56–60
   Google Scholar
• Gex-Fabry M, Balant-Gorgia A E, Balant L P. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46–53
   PubMed Web of Science ®Google Scholar
• Gossen D, De Suray J, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4: E11
   PubMed Web of Science ®Google Scholar
• Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153: 414–6
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153: 1631–3
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double blinded controlled study. J Clin Psychiatry 2000; 61: 26–9
   PubMed Web of Science ®Google Scholar
• Khan A, Warner H A, Brown W A. Symptoms reduction and suicide risk in patients treated with placebo in antidepressant clinical trails: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57: 311–7
   PubMed Web of Science ®Google Scholar
• Quitkin F M, McGrath P J, Stewart J W, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants?. Arch Gen Psychiatry 1996; 53: 785–92
   PubMed Web of Science ®Google Scholar
• Walsh B T, Seidman S N, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial and growing. JAMA 2002; 287: 1840–7
   PubMed Web of Science ®Google Scholar
• Nelson W H, Khan A, Orr W W, Jr. Delusional depression. Phenomenology, neuroendocrine function, and tricyclic antidepressant response. J Affect Disord 1984; 6: 297–306
   Google Scholar
• Roose S P, Glassman A H, Walsh B T, Woodring S, Vital-Herne J. Depression, delusions, and suicide. Am J Psychiatry 1983; 140: 1159–62
   PubMed Web of Science ®Google Scholar
• McKenzie M S, McFarland B H. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf 2007; 16: 513–23
   PubMed Web of Science ®Google Scholar
• Woerner M G, Alvir P H, Saltz B L, Lieberman J A, Kane J M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1988; 155: 1521–8
   Google Scholar
• Newcomer J W, Haupt D W. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480–91
   PubMed Web of Science ®Google Scholar
• Lambert M T, Copeland L A, Sampson N, Duffy S A. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 919–23
   PubMed Web of Science ®Google Scholar
• Chiu C C, Chen K P, Liu H C, Lu M L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol 2006; 26: 504–7
   PubMed Web of Science ®Google Scholar
• Aronson T, Shukla S, Hoff A. Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse. Convuls Ther 1987; 3: 251–9
   PubMedGoogle Scholar
• Kim W, Bahk W-M, Seo J S, et al. Depressive disorder with psychotic features. Annual meeting of the American Psychiatric Association, San Diego, CA, May, 2007, New Research NR 296
   Google Scholar
• Thase M E, Rush A J, Howland R H, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233–9
   PubMed Web of Science ®Google Scholar
• Khan A, Cohen S, Stowell M, Capwell R, Avery D, Dunner D L. Treatment options in severe psychotic depression. Convuls Ther 1987; 3: 93–9
   Google Scholar
• Price L H, Charney D S, Heninger G R. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986; 143: 1387–92
   PubMed Web of Science ®Google Scholar
• Price L H, Conwell Y, Nelson J C. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983; 140: 318–22
   PubMed Web of Science ®Google Scholar
• Nelson J C, Mazure C M. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986; 143: 363–6
   PubMed Web of Science ®Google Scholar
• Ranjan R, Meltzer H. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1995; 40: 253–8
   Google Scholar
• Jeyapaul P, Vieweg R. A case study evaluating the use of clozapine in depression with psychotic features. Ann Gen Psychiatry 2006; 5: 20
   Google Scholar
• Dassa D, Kaladjian A, Azorin J M, Giudicelli S. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993; 163: 822–4
   Google Scholar
• Jeste D. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004; 65(suppl 9)21–4
   PubMed Web of Science ®Google Scholar
• Kane J. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65(suppl 9)16–20
   PubMed Web of Science ®Google Scholar
• Khan A, Noonan C, Healey W. Is a single tricyclic antidepressant trial an active treatment for psychotic depression?. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 765–70
   Google Scholar
• Van d en, Broek W W, Birkenhäger T K, Mulder P G, Bruijn J A, Moleman P. A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology 2004; 175: 481–6
   Google Scholar
• Brujin J A, Moleman P, Mudler P G, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed inpatients. Psychopharmacology 1996; 127: 231–7
   Google Scholar
• Rothschild A, Phillips K. Selective serotonin reuptake inhibitors and delusional depression. Am J Psychiatry 1999; 156: 977–8
   PubMedGoogle Scholar
• Zanardi R, Franchini L, Perez J, Gasperini M, Smeraldi E. Dr. Zanardi and colleagues reply. Am J Psychiatry 1999; 156: 978
   Google Scholar
• Avery D, Lubrano A. Depression treated with imipramine and ECT: the DeCarolis study reconsidered. Am J Psychiatry 1979; 136: 559–62
   PubMedGoogle Scholar
• Osser D N, Patterson R D, Levitt J J. Guidelines, algorithms, and evidence-based psychopharmacology training for psychiatric residents. Acad Psychiatry 2005; 29: 180–6
   PubMed Web of Science ®Google Scholar
• Meyers B S, Peasley-Miklus C, Flint A J, Mulsant B H, Rothschild A J. Methodological issues in designing a randomized controlled trial for psychotic depression: the STOP-PD study. Psychiatr Ann 2006; 36: 57–64
   Google Scholar
• Mulsant B H, Haskett R F, Prudic J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry 1997; 154: 559–61
   Google Scholar